TrialCancer science2023

Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.

Tatsuya Yoshida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.